CLINICAL CASE DISCUSSIONSCPK Measurements and ECT in Polymyositis: A Case ReportDELUCIA, BENJAMIN MD; PATEL, RACHIT MD; YACOUB, ADEEB MD; FRANCIS, ANDREW PhD, MDAuthor Information DELUCIA, and YACOUB: Department of Psychiatry and Behavioral Science, School of Medicine, State University of New York at Stony Brook, Stony Brook, NY PATEL: Department of Psychiatry, Stamford Hospital, Stamford, CT FRANCIS: Department of Psychiatry, Penn State School of Medicine, Hershey PA The authors declare no conflicts of interest. Please send correspondence to: Benjamin DeLucia, MD, Department of Psychiatry and Behavioral Science, School of Medicine, State University of New York at Stony Brook, 101 Nicolls Road, Stony Brook, NY, 11794. [email protected]. Journal of Psychiatric Practice: November 2016 - Volume 22 - Issue 6 - p 481-483 doi: 10.1097/PRA.0000000000000191 Buy Metrics Abstract Inflammatory myopathies, including polymyositis (PM), may add risk to electroconvulsive therapy (ECT) due to muscle sensitivity to depolarizing neuromuscular agents. In addition, previously published case series have shown elevations in creatine phosphokinase (CPK), an index of PM disease severity, in patients without muscle disease receiving ECT. We report the case of a 74-year-old female who developed initial onset of depression after steroid treatment for biopsy-proven PM. After she failed to respond to trials of antidepressant medications, she was treated with 21 inpatient and outpatient sessions of ECT over 2 years. Each course of treatment was effective for her depression without worsening symptoms of muscle disease activity. Two previous cases have described the use of ECT in patients with inflammatory myopathies, but our case is the first to report maintenance phase treatment with CPK monitoring. Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.